CN1263869C - 病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 - Google Patents
病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 Download PDFInfo
- Publication number
- CN1263869C CN1263869C CNB031114520A CN03111452A CN1263869C CN 1263869 C CN1263869 C CN 1263869C CN B031114520 A CNB031114520 A CN B031114520A CN 03111452 A CN03111452 A CN 03111452A CN 1263869 C CN1263869 C CN 1263869C
- Authority
- CN
- China
- Prior art keywords
- probe
- hepatitis
- virus
- primer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 34
- 201000001862 viral hepatitis Diseases 0.000 title claims abstract description 34
- 238000003745 diagnosis Methods 0.000 title claims abstract description 27
- 238000004458 analytical method Methods 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 11
- 239000000523 sample Substances 0.000 claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 241000700605 Viruses Species 0.000 claims abstract description 23
- 238000009396 hybridization Methods 0.000 claims abstract description 20
- 208000006454 hepatitis Diseases 0.000 claims abstract description 16
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 16
- 238000005516 engineering process Methods 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 238000002493 microarray Methods 0.000 claims abstract description 8
- 239000002299 complementary DNA Substances 0.000 claims abstract description 7
- 239000011521 glass Substances 0.000 claims abstract description 7
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 5
- 238000003908 quality control method Methods 0.000 claims abstract description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 21
- 239000002751 oligonucleotide probe Substances 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 238000010367 cloning Methods 0.000 claims description 15
- 238000013518 transcription Methods 0.000 claims description 15
- 230000035897 transcription Effects 0.000 claims description 15
- 230000001154 acute effect Effects 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
- 241000709721 Hepatovirus A Species 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000711549 Hepacivirus C Species 0.000 claims description 7
- 238000013461 design Methods 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 241000709715 Hepatovirus Species 0.000 claims description 6
- 238000013016 damping Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 5
- 238000007405 data analysis Methods 0.000 claims description 5
- 208000005252 hepatitis A Diseases 0.000 claims description 5
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 3
- 241000531123 GB virus C Species 0.000 claims description 3
- 241000724675 Hepatitis E virus Species 0.000 claims description 3
- 208000037262 Hepatitis delta Diseases 0.000 claims description 3
- 241000724709 Hepatitis delta virus Species 0.000 claims description 3
- 101150010882 S gene Proteins 0.000 claims description 3
- 238000007781 pre-processing Methods 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 8
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LRJGJDKBKCTWKM-HZUJVAHNSA-N (4aR,8S,8aR)-2-(2-fluorophenyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]-1-oxo-3,4,4a,7,8,8a-hexahydroisoquinoline-8-carboxamide Chemical compound Cc1ccc(NC(=O)[C@H]2CC=C[C@H]3CCN(C(=O)[C@@H]23)c2ccccc2F)cc1C(F)(F)F LRJGJDKBKCTWKM-HZUJVAHNSA-N 0.000 description 1
- OQJGZGAYSCWFCK-UHFFFAOYSA-N 2-[4-(furan-2-ylmethyl)-5-[[4-methyl-3-(trifluoromethyl)phenyl]methylsulfanyl]-1,2,4-triazol-3-yl]pyridine Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1CSC(N1CC=2OC=CC=2)=NN=C1C1=CC=CC=N1 OQJGZGAYSCWFCK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
甲肝引物primer1.1primer1.2乙肝引物primer2.3primer2.4丙肝引物outer Primer3.3outer Primer3.4iner primer3.5iner primer3.6丁肝引物primer4.1primer4.2戊肝引物primer5.1primer5.2庚肝引物Primer6.1Primer6.2TTV引物Premer7.1Premer7.2 | Sequnce5`-TCCACATTTGGATTGGGATCTAGTCTCCTCCTGTC-5`Sequnce5`-GTGCCATTTGTTCAGTGGGATAACTAACCTTTCACA-5`Sequnce5`-GGCGACACTCCACCATAGATCTCCAGAGCATCTGGCACGTAG-5`5`-CTGTGAGGAACTACTGTCTTCACGAACACCATGACGGACTATCCCA-5`Sequnce5`-CCTTCAGCGAACAGAGTGAATAGCAGGGGTGT-5`Sequnce5`-CGGTCAGCCGTCTGCGAACCGCACTGGT-5`Sequnce5`-TGGTAGGTCGTAAATCCACTGTTCCTGGTCACC-5`Sequnce5`-CTGCAATCCATGTATGATACCATGTCTCCTTGTCATAT-5` | Seq No.670890Seq No.686991Seq No.632933290Seq No.321502Seq No.52125415Seq No.136401Seq No.13931697 |
甲肝探针Probe1.1Probe1.2乙肝探针ProbeProbe 2.1 | Sequnce5`-caaatgctatgttgtccactgagtc5`-caaatgccatgttgtccactgSequnce5`-ATCCCATCATCCTGGGCTTT | Seq No.Gene type797HAV797HAVSeq No.611 Gene type611 acute,adr,adyw,carcin |
Probe2.2Probe2.3Probe2.4Probe2.5Probe2.6Probe2.7Probe2.8Probe2.9Probe2.10Probe2.11Probe2.12Probe2.13Probe2.14Probe2.15Probe2.16Probe2.17Probe2.18Probe2.19Probe2.20Probe2.21Probe2.22Probe2.23Probe2.24Probe2.25Probe2.26Probe2.27Probe2.28Probe2.29Probe2.30Probe2.31Probe2.31Probe2.32Probe2.33丙肝探针Probe3.1 | 5`-CCCATCATCTTTGGCTTTCG5`-ATCCCATCGTCCTGGGCT5`-ATCCCATCATCTTGGGCTTTC5`-ATCCCATCATCTTGGGGTTTC5`-TGGGCTTTCGGAAAATTCC5`-TGGGCTTTCGCAAGATTCC5`-TTGGCTTTCGCAAGATTCCT5`-TGGGCTTTCGCAAAATACCT5`-TGGGCTTTCGCAAAATTC5`-TCAGCCCGTTTCTCTTGGC5`-CAGCCCGTTTCTCCTGGC5`-GGCCTCGGTCCGTTTCTC5`-TGGTTCGTAGGGCTTTCCC5`-AGTGGT TCGCAGGGCTTTC5`-GCTTTCAGTTATATGGATGATGTGGT5`-CTTTCAGTTATATGGATGATCTGGTATT5`-CTTTCAGCTATATGGATGATGTGGT5`-CTTTCAGTTATANGGATGACGTGG5`-GCTTTCAGCTATATAGATGATGTGGTA5`-TCTGTACAGCATCTTGAGTCCCTT5`-TCTGTACAACATCT TGAGTCCCTTT5`-TCTGTGCAACATCTTGAGTCCC5`-TCTGTACAGCATCGTGAGTCCC5`-TCTGTACAACATCTTGAATCCCTTT5`-CACAAAATCAAAGAATGTTTTAGAAAA5`-TTAAAACTCAAACAATGTTTTCGGA5`-CTAAAACTCAAGCAATGTTTTCGAA5`-CTCAAAATTAAGCAATGTTTTCGAA5`-CAAAAAATCAAAATGTGTTTTAGGAA5`-CACAAACTCAAACACTGTTTTAGAAAA5`-AGAAAAATCAAAATGTGTTTTAGGAAA5`-AGAAAAATCAAAATGTGTTTTAGGA5`-CAAAAGATCAAACACTGTTTTAGAAAASequnce5`-TGGTACTGCCTGATAGGGTGC | oma,negtive,611anti-drug611anti-drug,adw2611chronic,adw,wild623ayw623adywacute,adr,carcinoma,n623egtive,623anti-druganti-drug,adw,adw2,w623ild656chronic,adw,wild656adyw652carcinomanegtiveadr,carcinoma,adyw,chroni701c,adw,adw2,wild,anti-drug730acute,ayw,negtiveacute,negtive,carcinoma,adyw,chronic,adw,730wild730ayw730adw2730anti-drug769anti-drug769adywacute,carcinoma,negti769ve,ayw,adw,wild769chronic769adw2931adr931adyw931acute,negtive931adr931carcinoma931chronic931ayw931adw931wildadw2SeqNo.Gene type272HCV |
Probe3.2丁肝探针Probe4.1Probe4.2Probe4.3Probe4.4probe4.5Probe4.6Probe4.7Probe4.8Probe4.9Probe4.10戊肝探针Probe5.1Probe5.2Probe5.3Probe5.4庚肝探针Probe6.1Probe6.2Probe6.3Probe6.4Probe6.5TTV探针Probe7.1Probe7.2 | 5`-TGGATCAACCCGCTCAATGSequnce5`-GAGCGCATCGCAGAGGG5`-GAGCGCATCGCGAGAGG5`-GGGGCGCATCGCGA5`-GAGCGCTCGGGTGGTAGG5`-AGCTCTGACGCGCGAGG5`-GACCCTGGTACCGGGGG5`-AGGCGCTTCGAGCGGTA5`-AGACTCTCTTCCCGGTGGGA5`-GGCTCTCTCACGCGGTAGG5`-GAGCTCCCTCCTCCTCCTTCSequnce5`-GGACCTCGTGTTCGCCAAC5`-GCCCTCGGCAGCCAAT5`-CCTCGACAGCCGCCCC5`-GACCTCGCGTTCGCCAASequnce5`-AGCCCGTCACCCACCTG5`-GCCCGTAACCCGCCTG5`-GCCCATTACCCACCTGGG5`-AGCCCGTTACCCACCTGG5`-TACGGTCCACGTCGCCCSequnce51-AGCAACAACATGGGCATCATAC5`-AGCAACAACATGGGGATCATAC | 187HCVSeqNo.Gene type336Quebec hdv336Venezuela hdv336Acute hdv336Italy hdv336TW2667336Venzuela336C.A.P336African336Smalian336TW2476Seq No.Gene type5363HDV5369Chinese5372JRA15363IndianSeqNo.Gene type296Iowan,China296Serum296HGVCN296USA,PNF2161330HGVSeq No.Gene type1560TTV1560pTZVT416 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031114520A CN1263869C (zh) | 2003-04-14 | 2003-04-14 | 病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031114520A CN1263869C (zh) | 2003-04-14 | 2003-04-14 | 病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1515689A CN1515689A (zh) | 2004-07-28 |
CN1263869C true CN1263869C (zh) | 2006-07-12 |
Family
ID=34239242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031114520A Expired - Fee Related CN1263869C (zh) | 2003-04-14 | 2003-04-14 | 病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1263869C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948922A (zh) * | 2010-09-21 | 2011-01-19 | 天津生物芯片技术有限责任公司 | 一种固相dna芯片杂交液及杂交方法 |
CN108018376B (zh) * | 2016-10-31 | 2020-11-03 | 深圳华大因源医药科技有限公司 | 一种用于丙肝病毒分型和耐药位点检测的探针和方法 |
CN111575411B (zh) * | 2020-06-04 | 2021-03-02 | 昆明寰基生物芯片产业有限公司 | 血源性感染病原体核酸标记试剂盒及使用方法 |
-
2003
- 2003-04-14 CN CNB031114520A patent/CN1263869C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1515689A (zh) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111197112A (zh) | 一种检测新型冠状病毒的引物、探针及试剂盒 | |
KR20100116954A (ko) | 실시간 중합효소 연쇄반응을 통한 hbv 검출 방법 | |
CN1195070C (zh) | 一种检测多种传染病的检测型基因芯片及应用 | |
CN1840700A (zh) | 小反刍兽疫病毒荧光定量rt-pcr检测试剂及制备方法和应用 | |
CN1263869C (zh) | 病毒性肝炎集成诊断及耐药分析芯片及其制备工艺和使用方法 | |
CN1549864A (zh) | 用于预测癌症复发的评定体系 | |
CN100351630C (zh) | 对虾ihhnv的fq-pcr诊断试剂盒及检测方法 | |
CN101051026A (zh) | 耐万古霉素肠球菌双重实时荧光pcr检测方法 | |
CN1814806A (zh) | 安氏隐孢子虫pcr检测试剂盒 | |
CN101078025A (zh) | 一种检测copd的snp的pcr试剂盒 | |
CN106434943A (zh) | 一种用于阿司匹林个体化用药相关基因snp检测的试剂盒及其检测方法 | |
CN1847408A (zh) | 一种血小板糖蛋白hpa-1和hpa-2基因型检测芯片及其用途 | |
CN1588066A (zh) | 乙型肝炎病毒基因分型的荧光pcr检测方法及其试剂盒 | |
CN101041860A (zh) | 丹参素相关基因的检测芯片、制备及检测方法 | |
CN104946735A (zh) | 试剂盒及确定待测dna样本预定snp位点的基因型的方法 | |
CN1932037A (zh) | 一种筛查转基因小麦的方法 | |
CN1468965A (zh) | Sars病毒的基因检测试剂盒及检测方法 | |
CN1410761A (zh) | 实时荧光定量rt-pcr检测人细胞角蛋白19试剂盒 | |
CN111004868A (zh) | 一种用于检测山羊鼻内肿瘤病毒的荧光pcr引物、探针及试剂盒 | |
KR101019952B1 (ko) | 뇌졸중 조기진단 칩 그리고 이를 이용한 뇌졸중 스크리닝검사 | |
CN1339608A (zh) | 乙型肝炎病毒基因分型和基因变异诊断芯片 | |
CN1243107C (zh) | 一种pcr检测sars病毒基因的方法 | |
CN1884580A (zh) | 检测表皮生长因子受体基因位点突变的荧光定量pcr试剂盒 | |
CN1526830A (zh) | 个体化用药基因型诊断芯片及其制造方法和应用方法 | |
CN1126819C (zh) | 均相分子灯标荧光探针pcr乙肝病毒检测方法和试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHINA MEDICINE UNIVERSITY Free format text: FORMER OWNER: ZHAO YUJIE; HE QUN; HOU WEIJIAN Effective date: 20060818 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060818 Address after: 110001, No. two, 92 North Road, Heping District, Liaoning, Shenyang Patentee after: China Medical Univ. Address before: 110001 biological center, 92 north two road, Heping District, Liaoning, Shenyang Co-patentee before: He Qun Patentee before: Zhao Yujie Co-patentee before: Hou Weijian |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060712 Termination date: 20170414 |